Current anti-CTLA-4 monoclonal antibodies have been less efficacious than expected in clinical trials, and Samuel Murphy, PhD, Salubris Bio, Gaithersburg, MD, discusses the development of JK08, an IL-15 antibody fusion protein targeting CTLA-4. Addition of an IL-15 domain will theoretically expand the natural killer (NK) cell population in addition to depleting regulatory T cells (Tregs), which will enhance the immune response. A Phase I/II dose-expansion trial (NCT05620134) is underway to assess the investigational therapy in advanced solid tumors. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
